<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02373904</url>
  </required_header>
  <id_info>
    <org_study_id>14-03-PATHOLHUM-01</org_study_id>
    <secondary_id>NL49653.072.14</secondary_id>
    <nct_id>NCT02373904</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of the Treatment of Impending and Actual Pathological Fractures in the Humerus From Metastatic Bone Disease</brief_title>
  <official_title>A Prospective, Multi-Center Study of the IlluminOss Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pathological Fractures in the Humerus From Metastatic Bone Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlluminOss Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlluminOss Medical, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect safety and performance data of the Photodynamic Bone
      Stabilization System (PBSS) when used for the treatment of painful impending and actual
      fractures of the humerus secondary to metastatic cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Reduction</measure>
    <time_frame>90 days</time_frame>
    <description>VAS Pain Score change of &gt; -33% compared to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Improvement (Barthel Index of Activities of Daily Living (ADLs) improvement of &gt; +10% from baseline -EORTC QLQ-C30 improvement of &gt; +10% from baseline -EORTC QLQ-BM22 improvement of &gt; +10% from baseline)</measure>
    <time_frame>90 days</time_frame>
    <description>Barthel Index of Activities of Daily Living (ADLs) improvement of &gt; +10% from baseline
EORTC QLQ-C30 improvement of &gt; +10% from baseline
EORTC QLQ-BM22 improvement of &gt; +10% from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Safety Success (No Serious Device Related Complications -No additional surgical interventions: revisions, supplements, fixations or removals)</measure>
    <time_frame>90 days</time_frame>
    <description>No Serious Device Related Complications
No additional surgical interventions: revisions, supplements, fixations or removals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiographic Safety Success (No device fracture, migrations, mal-alignment or loss of reduction or fixation)</measure>
    <time_frame>90 days</time_frame>
    <description>No device fracture, migrations, mal-alignment or loss of reduction or fixation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Reduction (VAS Pain Score change of &gt; -33% compared to baseline)</measure>
    <time_frame>90, 180 and 360 days</time_frame>
    <description>VAS Pain Score change of &gt; -33% compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Improvement (-Barthel Index of Activities of Daily Living (ADLs) improvement of &gt; +10% from baseline, -EORTC QLQ-C30 improvement of &gt; +10% from baseline -EORTC QLQ-BM22 improvement of &gt; +10% from baseline)</measure>
    <time_frame>90, 180, 360 days</time_frame>
    <description>Barthel Index of Activities of Daily Living (ADLs) improvement of &gt; +10% from baseline,
EORTC QLQ-C30 improvement of &gt; +10% from baseline
EORTC QLQ-BM22 improvement of &gt; +10% from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Safety Success (No Serious Device Related Complications -No additional surgical interventions: revisions, supplements, fixations or removals)</measure>
    <time_frame>90, 180, 360 days</time_frame>
    <description>No Serious Device Related Complications
No additional surgical interventions: revisions, supplements, fixations or removals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic Safety Success (No device fracture, migrations, mal-alignment or loss of reduction or fixation)</measure>
    <time_frame>90, 180, 360 days</time_frame>
    <description>No device fracture, migrations, mal-alignment or loss of reduction or fixation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of index procedure and length of hospital stay</measure>
    <time_frame>90, 180, 360 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability status</measure>
    <time_frame>90, 180, 360 days</time_frame>
    <description>Determined per Investigator assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of duration of physical therapy prescription</measure>
    <time_frame>90, 180, 360 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of prescription and over-the-counter analgesic medication use</measure>
    <time_frame>90, 180, 360 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survivability from time of index procedure to death</measure>
    <time_frame>90, 180, 360 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and number of AEs</measure>
    <time_frame>90, 180, 360 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and number of procedure- and device-related complications</measure>
    <time_frame>90, 180, 360 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of Daily Living score through all follow-up intervals</measure>
    <time_frame>90, 180, 360 days</time_frame>
    <description>Barthel Index of Activities of Daily Living (ADLs), EORTC QLQ-C30 and EORTC QLQ-BM22</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Pain score from baseline through all follow-up intervals</measure>
    <time_frame>90, 180, 360 days</time_frame>
    <description>VAS pain scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Humerus Pathological Fracture</condition>
  <arm_group>
    <arm_group_label>Photodynamic Bone Stabilization System (PBSS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The PBSS is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter. This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Photodynamic Bone Stabilization System</intervention_name>
    <description>Treatment of impending and actual pathological fractures of the humerus</description>
    <arm_group_label>Photodynamic Bone Stabilization System (PBSS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -General Inclusion Criteria

          1. Skeletally mature adult males and females 18 years of age or older.

          2. Impending or actual pathological fracture of the humerus, secondary to metastatic bone
             disease.

          3. Females: neither pregnant nor intending to become pregnant during the course of the
             study, defined as:

               1. Postmenopausal for at least 1 year OR

               2. Documented oophorectomy or hysterectomy

               3. Surgically sterile OR

               4. If of childbearing potential, must be practicing double-barrier method of birth
                  control, be willing to avoid pregnancy for the period of study participation and
                  have a negative pregnancy test at screening

          4. Able to understand and provide informed consent.

          5. Willing and able to comply with post-operative treatment protocol and follow-up visit
             schedule.

             -Impending Fracture-Specific Inclusion Criteria

          6. Documented presence of solitary metastatic lesion.

          7. Mirels Criteria Score ≥ 8.

          8. Destruction of cortical bone at impending fracture site &gt; 50%.

             -Actual Fracture-Specific Inclusion Criteria

          9. Radiograph-confirmed diagnosis of acute, single isolated fracture of the humerus. AO
             classification 11A1, 11A2 and 11B1, 11B2 and 12A1,12A2 and 12B1, 12B2 and 13A1,13A2
             and 13B1, 13B2.

         10. Fracture is closed, Gustilo Type I or IIA.

        Exclusion Criteria:

        -General Exclusion Criteria

          1. Primary tumor (osteogenic origin, etc.) at site.

          2. Impending fracture or actual fracture location other than humerus.

          3. Current concomitant traumatic fracture of any other location.

          4. Active or incompletely treated infections that could involve the device implant site.

          5. Distant foci of infection that may spread to the implant site.

          6. Allergy to implant materials or dental glue.

          7. Vascular insufficiency, muscular atrophy, or neuromuscular disease at implant site.

          8. Uncooperative patients, or patients who are incapable of following directions (for
             example, as a consequence of a neurological or psychiatric disorder).

             -Impending Fracture-Specific Exclusion Criteria

          9. Mirels Score &lt; 8.

         10. Destruction of cortical bone at impending fracture site &lt; 50%.

         11. Prior surgery and/or prior fracture of affected site.

         12. Any articular component to impending fracture site.

             -Actual Fracture-Specific Exclusion Criteria

         13. Index treatment is greater than 28 days post fracture.

         14. Open fractures with severe contamination.

         15. Extremely comminuted fractures where insufficient holding power of the balloon on the
             intramedullary canal is probable.

         16. Delivery sheath is unable to cross fracture site after proper fracture reduction and
             realignment

         17. Patients whose intramedullary canal at site of fracture measures smaller than the
             diameter of the sheath provided.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vinzenz-Hospital GmbH</name>
      <address>
        <city>Koln</city>
        <zip>D-50733</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahn-Dill Kliniken</name>
      <address>
        <city>Wetzlar</city>
        <zip>35578</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <zip>7513 ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2015</study_first_submitted>
  <study_first_submitted_qc>February 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2015</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Fractures, Spontaneous</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>January 15, 2018</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>March 5, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

